Investigation of the effects of deracoxib and piroxicam on the in vitro viability of osteosarcoma cells from dogs

American Journal of Veterinary Research

Volumn 66, Issue 11, 2005, Pages 1961-1967

  Royals, Stephen R ^a   Farese, James P ^a   Milner, Rowan J ^a   Lee Ambrose, Linda ^a   van Gilder, James ^a  

^a University of Florida College of Veterinary Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DERACOXIB; DNA FRAGMENT; PIROXICAM; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL ASSAY; CELL COUNT; CELL GROWTH; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOG; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENCY; FIBROBLAST CULTURE; IC 50; IN VITRO STUDY; INCUBATION TIME; NONHUMAN; OSTEOSARCOMA CELL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; BONE NEOPLASMS; CELL COUNT; CELL LINE, TUMOR; CELL SURVIVAL; DNA FRAGMENTATION; DOG DISEASES; DOGS; ELECTROPHORESIS, AGAR GEL; FORMAZANS; INHIBITORY CONCENTRATION 50; OSTEOSARCOMA; PIROXICAM; SULFONAMIDES; TETRAZOLIUM SALTS;

ANIMALIA; CANIS FAMILIARIS;

EID: 30744459597     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2005.66.1961     Document Type: Article

References (58)

1. Brodey RS, Riser WH. Canine osteosarcoma: a clinicopathological study of 194 cases. Clin Orthop 1969;62:54-64.
2. Ling GV, Morgan JP, Pool RR. Primary bone tumors in the dog: a combined clinical, radiological, and histological approach to early diagnosis. J Am Vet Med Assoc 1974;165:55-67.
3. Brodey RS, Sauer RM, Medway W. Canine bone neoplasms. J Am Vet Med Assoc 1963;143:471-495.
4. Withrow SJ, Powers BE, Straw RC, et al. Comparative aspects of osteosarcoma: dog vs. man. Clin Orthop 1991;270:159-167.
5. Heyman SJ, Diefenderfer DL, Goldschmidt MH, et al. Canine axial skeletal osteosarcoma: a retrospective study of 116 cases (1986 to 1989). Vet Surg 1992;21:304-310.
6. Spodnick GJ, Berg RJ, Rand WM, et al. Prognosis for dogs with appendicular osteosarcoma treated with amputation alone: 162 cases (1978-1988). J Am Vet Med Assoc 1992;200:995-999.
7. Dernell WS, Straw RC, Withrow SJ. Tumors of the skeletal system. In: Withrow SJ, MacEwen EG, eds. Small animal clinical oncology. 3rd ed. Philadelphia: WB Saunders Co, 2001;378-403.
8. Liptak JM, Dernell WS, Ehrhart N, et al. Canine appendicular osteosarcoma: curative-intent treatment. Compend Contin Educ Pract Vet 2004;26:186-196.
9. Farese JP, Milner RJ, Thompson MS, et al. Stereotactic radiosurgery for the treatment of lower extremity osteosarcoma in dogs. J Am Vet Med Assoc 2004;225:1567-1572.
10. Bergman PJ, MacEwen EG, Kurzman ID. Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991-1993). J Vet Intern Med 1996;10:76-81.
11. Mauldin GN, Matus RE, Withrow SJ. Canine osteosarcoma treatment by amputation versus amputation and adjuvant chemotherapy using doxorubicin and cisplatin. J Vet Intern Med 1988;2:177-180.
12. Chun R, Kurzman ID, Couto G, et al. Cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma: preliminary findings. J Vet Intern Med 2000;14:495-498.
13. Berg J, Gebhard MC, Rand WM. Effect of timing on postoperative chemotherapy on survival of dogs with osteosarcoma. Cancer 1997;79:1343-1350.
14. Pestili de Almedia EM, Piche C, Sirois J, et al. Expression of cyclooxygenase-2 in naturally occurring squamous cell carcinomas in dogs. J Histochem Cytochem 2001;49:867-875.
15. Khan KNM, Knapp DW, DeNicola DB, et al. Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in dogs. Am J Vet Res 2000;61:478-481.
16. Knapp DW, Chan TCK, Kuczek T, et al. Evaluation of in vitro cytotoxicity of nonsteroidal anti-inflammatory drugs against canine tumor cells. Am J Vet Res 1995;56:801-805.
17. Knapp DW, Glickman NW, Widemer WR, et al. Cisplatin versus cisplatin with piroxicam in a canine model of human invasive urinary bladder cancer. Cancer Chemother Pharmacol 2000; 46:221-226.
18. Knapp DW, Richardson RC, Bottons GD, et al. Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors. Cancer Chemother Pharmacol 1992;29:214-218.
19. Knapp DW, Richardson RC, Chan TCK, et al. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1994;8:273-278.
20. Mohammed SI, Bennett PF, Craig BA, et al. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res 2002;62:356-358.
21. Schmidt BR, Glickman NW, DeNicola DB, et al. Evaluation of piroxicam for the treatment of oral squamous cell carcinoma in dogs. J Am Vet Med Assoc 2001;218:1783-1786.
22. Sorenmo KU, Goldschmidt FS, Shofer FS, et al. Evaluation of cyclooxygenase-1 and cyclooxygenase-2 expression and the effect of cyclooxygenase inhibitors in canine prostatic carcinoma. Vet Comp Oncol 2004;2:13-23.
23. Dannenberg AJ, Altorki NK, O Boyle J, et al. Cyclooxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2001;2:544-551.
24. Raz A. Is inhibition of cyclooxygenase required for the anti-tumorigenic effects of nonsteroidal, anti-inflammatory drugs? In vitro versus in vivo results and the relevance for the prevention and treatment of cancer. Biochem Pharmacol 2002;63:343-347.
25. Scioscia KA, Snyderman CH, Rueger R, et al. Role of arachidonic acid metabolites in tumor growth inhibition by nonsteroidal anti-inflammatory drugs. Am J Otolaryngol 1997;18:1-8.
26. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 1998;90:1529-1536.
27. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J Natl Cancer Inst 1998;90:1609-1620.
28. Thun MJ, Henly SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252-266.
29. Vane JR, Bakle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120.
30. Alshafie GA, Abou-Issa HM, Seibert K, et al. Chemotherapeutic evaluation of Celecoxib, a cyclooxygenase-2 inhibitor, in a rat mammary tumor model. Oncol Rep 2000;7:1377-1381.
31. Calaluce R, Earnest DL, Heddens D, et al. Effects of piroxicam on prostaglandin E2 levels in rectal mucosa of adenomatous polyp patients: a randomized phase IIb trial. Cancer Epidemiol Biomarkers Prev 2000;9:1287-1292.
32. Grosch S, Tegeder I, Niederberger E, et al. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001;15:2742-2744.
33. Kawamori T, Rao CV, Seibert K, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998;58:409-412.
34. Kern MA, Schubert D, Sahi D, et al. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology 2002;36:885-894.
35. Rahman MA, Dhar DK, Masunga R, et al. Sulindac and exisulind exhibit a significant antiproliferative effect and induce apoptosis in human hepatocellular carcinoma cell lines. Cancer Res 2000;60:2085-2089.
36. Sheng GG, Shao J, Sheng H, et al. A selective cyclooxygenase 2 inhibitor suppresses the growth of h-ras-transformed rat intestinal epithelial cells. Gastroenterology 1997;113:1883-1891.
37. Song X, Lin HO, Johnson AJ, et al. Cyclooxygenase-2, player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst 2002;9:585-591.
38. Tomozawa S, Nagawa H, Tsuno N, et al. Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. Br J Cancer 1999;81:1274-1279.
39. Sabino MC, Ghilardi JR,Jongen JL, et al. Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Cancer Res 2002;62:7343-7349.
40. Mohammed SI, Coffman K, Glickman NW, et al. Prostaglandin E2 concentrations in naturally occurring canine cancer. Prostaglandins Leukot Essent Fatty Acids 2001;64:1-4.
41. Mohammed SI, Khan KNM, Sellers RS, et al. Expression of cyclooxygenase-1 and 2 in naturally-occurring canine cancer. Prostaglandins Leukot Essent Fatty Acids 2004;70:479-483.
42. Mullins MN, Ehrhart EJ, Lana SE, et al. Cyclooxygenase-2 expression in canine appendicular osteosarcomas. J Vet Intern Med 2004;18:859-865.
43. Kadosawa T, Nozaki K, Sasaki N, et al. Establishment and characterization of a new canine cell line from a canine osteosarcoma. J Vet Med Sci 1994;56:1167-1169.
44. Barroga EF, Kadosawa T, Okumura M, et al. Establishment and characterization of the growth and pulmonary metastasis of a highly metastasizing cell line from canine osteosarcoma in nude mice. J Vet Med Sci 1999;61:361-367.
45. Shoieb AM, Hahn KA, Barnhill MA. An in vivo/in vitro experimental model system for the study of human osteosarcoma: canine osteosarcoma cells (COS31) which retain osteoblastic and metastatic properties in nude mice. In Vivo 1998;12:463-472.
46. Yamashita H, Osaki M, Honjo S, et al. A selective cylooxygenase-2 inhibitor, NS-398, inhibits cell growth by cell cycle arrest in a human malignant fibrous histiocytoma cell line. Anticancer Res 2003;23:4671-4676.
47. Kulp SK, Yang YT, Hung CC, et al. 3-Phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res 2004;64:1444-1451.
48. Zhang Z, Lai GH, Sirica AE. Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepatology 2004;39:1028-1037.
49. Vona-Davis L, Riggs DR, Jackson BJ, et al. Antiproliferative effects of rofecoxib on esophageal cancer in vitro(1). J Surg Res 2004;119:143-148.
50. Baoping Y, Guoyong H, Jieping Y, et al. Cyclooxygenase-2 inhibitor nimesulide suppresses telomerase activity by blocking Akt/PKB activation in gastric cancer cell lines. Dig Dis Sci 2004;49:948-953.
51. Nishikawa M, Stapleton PP, Freeman TA, et al. NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model. J Am Coll Surg 2004;199:428-435.
52. Deracoxib [package insert]. Greensboro, NC: Novartis Animal Health US Inc, 2004.
53. Hsu AL, Ching TT, Wang DS, et al. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking AKT activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000;275:11397-11403.
54. Erickson BA, Longo WE, Panesar N, et al. The effects of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis. J Surg Res 1999;81:101-107.
55. Slingerland JM, Tannock IF. Cell proliferation and cell death. In: Tannock IF, Hill RP eds. The basic science of oncology. 3rd ed. New York: McGraw-Hill Book Co, 1998;134-165.
56. Sonnemann J, Eckervogt V, Truckenbrod B, et al. The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs 2001;12:459-465.
57. Moalic S, Liagre B, Le Bail JC, et al. Dose-dependent modulation of apoptosis and cyclooxygenase-2 expression in human 1547 osteosarcoma cells by NS-398, a selective cyclooxygenase-2 inhibitor. Int J Oncol 2001;18:533-540.
58. Gately S, Li WW. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 2004;31 (suppl 7):2-11.